10108. Zafirlukast

Nomenclature

CAS number: 107753-78-6
N-[3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamic acid cyclopentyl ester; cyclopentyl 3-[2-methoxy-4-[(o-tolylsulfonyl)carbamoyl]benzyl]-1-methylindole-5-carbamate; N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulfonamide; ICI-204219; Accolate (AstraZeneca).
C31H33N3O6S; mol wt 575.68.
C 64.68%, H 5.78%, N 7.30%, O 16.68%, S 5.57%.

Description and references

Cysteinyl leukotriene type 1 receptor antagonist. Prepn: F. J. Brown et al., EP 199543; P. R. Bernstein et al., US 4859692 (1986, 1989 both to ICI); V. G. Matassa et al., J. Med. Chem. 33, 1781 (1990). Improved prepn: K. Srinivas et al., Org. Process Res. Dev. 8, 952 (2004). Electrochemical characterization and voltammetric determn in pharmaceutical formulations: I. Süslü, S. Altinz, J. Pharm. Biomed. Anal. 39, 535 (2005). Preclinical pharmacology: R. D. Krell et al., Am. Rev. Respir. Dis. 141, 978 (1990). Effect on allergen-induced bronchoconstriction: S. R. Findlay et al., J. Allergy Clin. Immunol. 89, 1040 (1992); K. M. O'Shaughnessy et al., Am. Rev. Respir. Dis. 147, 1431 (1993). Clinical evaluation in bronchial asthma and allergic rhinitis: G. Piatti et al., Pharmacol. Res. 47, 541 (2003); in acute asthma: R. A. Silverman et al., Chest 126, 1480 (2004). Review of pharmacology and clinical efficacy in asthma: C. J. Dunn, K. L. Goa, Drugs 61, 285-315 (2001); of clinical pharmacokinetics: P. N. R. Dekhuijzen, P. P. Koopmans, Clin. Pharmacokinet. 41, 105-114 (2002).

Chemical structure

Properties

White solid from methanol, mp 138-140°. Slightly sol in methanol; freely sol in tetrahydrofuran, acetone, DMSO. Practically insol in water.

Therapeutic Category

Antiasthmatic.

Keywords

Antiasthmatic (Nonbronchodilator); Leukotriene Antagonist